price
Get this report for lesser with our subscription services
While subscription services provide a hassle-free experience and cost savings.
GO TO SECTION:
Speak With Us
Want to know more about the report or any specific requirement?
About The Report
DOWNLOAD SAMPLE“Gain valuable insights into the trends, innovations, and growth drivers shaping the global premature ejaculation therapeutics market. This report delves into the burgeoning market of therapeutics for premature ejaculation (PE), a condition affecting a significant portion of the global population. With the high prevalence of PE, market players are channeling their efforts into developing innovative drug formulations to effectively manage the condition, thereby contributing to the market's growth.”
The global premature ejaculation (PE) therapeutics market is experiencing significant growth, valued at $2,456.71 million in 2023 and projected to reach $4,062.34 million by 2029, growing at a CAGR of 8.74%. The market's expansion is largely driven by the increasing prevalence of PE among men globally.
Premature ejaculation is a prevalent sexual problem, affecting about 20-30% of men in the sexually active age group. This condition not only causes psychological stress but also impacts self-esteem. The highest incidence is reported among the 18 to 30-year-old age group and, along with erectile dysfunction, in the 45 to 65-year-old age group. PE prevalence varies among different ethnic groups, with higher rates reported among African Americans compared to Hispanics or Whites.
In 2023, North America and Europe dominated the market, while the Asia-Pacific region is expected to be the fastest-growing market for PE therapeutics, with a CAGR of 10.56%.
The North American region, particularly the United States, leads in revenue generation, followed by Europe, Asia-Pacific, Latin America, and the Middle East and Africa (MEA). North America also has the highest incremental growth, fueling the global PE therapeutics market.
By drug class, Selective Serotonin Reuptake Inhibitors (SSRIs) dominate the market, followed by Phosphodiesterase type 5 inhibitors (PDE5-Is), anesthetic agents, and others. SSRIs, including dapoxetine (the only licensed drug for PE treatment in certain countries), along with off-label medications, are widely used for PE treatment.
There is a notable demand for disposable syringes in developing economies due to the high cost of sterilization processes for reusable syringes. Safety and prefilled syringes are also increasingly preferred as they reduce risks to medical professionals and ensure accurate drug dosage to patients.
The global PE therapeutics market is witnessing strategic initiatives by key vendors, leading to intensifying market competitiveness. Major players like Pfizer, Bayer, Eli Lilly and Company, and GlaxoSmithKline offer off-label drugs for PE treatment, with physicians prescribing well-known brands as off-label medications for this condition.
In summary, the global PE therapeutics market is growing, characterized by pharmaceutical companies and generic manufacturers offering off-label branded drugs and generics, with strategic acquisitions and partnerships shaping the competitive landscape.
KEY HIGHLIGHTS
- The global premature ejaculation therapeutics market was valued at $2,456.71 million in 2023 and is expected to reach $4,062.34 million by 2029, growing at a CAGR of 8.74%. The market growth is mainly attributed to the rising prevalence of premature ejaculation among men globally.
- In 2023, North America and Europe dominated the market with more than 60% share collectively. APAC is expected to be the fastest-growing market for premature ejaculation (PE) therapeutics in terms of revenue during the forecast period.
- By drug class, the Selective Serotonin Reuptake Inhibitors (SSRIs) segment was valued at $1,064.41 million in 2023. The increased recommendation of SSRIs by healthcare professionals is one of the key factors for the growth of the segment worldwide. SSRIs are considered effective drugs for the treatment of premature ejaculation therapeutics market.
- The increased recommendation of oral therapeutics by healthcare professionals is one of the key factors for the growth of the oral therapeutics market worldwide. Also, the growing pervasiveness of premature ejaculation and the increasing uptake of generic off-label medications are the key factors enabling the growth of the oral ROA segment.
- The rise in the prevalence of premature ejaculation in the younger population is the major factor contributing to the market growth during the forecast period. The people aged below 45 years segment is going to drive the demand for premature ejaculation threapeutics.
- Plethora Solutions, Pfizer, Eli Lilly and Company, GSK plc, and the Menarini group are some of the leading players currently dominating the global premature ejaculation therapeutics market. The major players focus on strategic acquisitions and collaborations with emerging players to enter the premature ejaculation therapeutics market and access commercially launched products.
Client Oriented Solutions
Arizton provides in-depth market insights and intelligence across various sectors, including Automotive & Mobility, Data Centers, Consumer Goods, and Healthcare & Lifesciences.
Analytical Approach
Arizton focuses on providing information related to key issues facing the industry, Existing market landscape, regulatory concerns, risk & opportunities, technology evolution, future commercial potential.
Comprehensive Data Repository
The reports provide historical and forecast data for 20+ key countries worldwide. We track product approvals/launches, M&A activities, and collaboration/partnership activities.
Publication Analysis
Arizton delivers timely industry updates and customized insights by analyzing peer-reviewed research and business publications.
price
Get this report for lesser with
our subscription services
Summary
REPORT HIGHLIGHTS
PRODUCT SEGMENTATION AND FORECAST
- Drug Class
- Selective Serotonin Re-uptake Inhibitors (SSRIs)
- Phosphodiesterase type 5 (PDE5) inhibitors
- Anesthetic Agents
- Others
- Route of Administration
- Oral Therapeutics
- Topical Therapeutics
- Age Group
- Below 45 years
- Above 45 years
Key Vendors
- Plethora Solutions
- Absorption Pharmaceuticals
- Pfizer
- Eli Lilly and Company
- GSK plc
- Bayer AG
- MidasCare
- Pound International
- Momentum Management
- Reckitt Benckiser Group
- Recordati
- Royalty Pharma
- Shibari
- The Menarini Group
- Johnson & Johnson
- Futura Medical
- Niksan Pharmaceuticals
- Amneal Pharmaceuticals
Report Preview
DOWNLOAD SAMPLEPlease Note : Arizton critically analyzes the industry and market sectors to provide reliable and valuable market intelligence. The research-based knowledge empowers clients to formulate intelligent strategies, resulting in creative, cost-effective, and efficient execution.
Table Of Contents
- Executive Summary
- Key Findings
- GLOBAL: Projected Revenue by Drug Class (2023-2029; $Millions)
- SSRIs
- PDE-5 Inhibitors
- Anesthetic Agents
- Others
- GLOBAL: Projected Revenue by Route of Administration (2023-2029; $Millions)
- Oral Therapeutics
- Topical Therapeutics
- GLOBAL: Projected Revenue by Age Group (2023-2029; $Millions)
- Below 45 years
- Above 45 years
- North America: Projected Revenue of PE Therapeutics Market (2023-2029; $Millions)
- Projected Revenue of PE Therapeutics Market in US
- Projected Revenue of PE Therapeutics Market in Canada
- Europe: Projected Revenue of PE Therapeutics Market (2023-2029; $Millions)
- Projected Revenue of PE Therapeutics Market in Germany
- Projected Revenue of PE Therapeutics Market in UK
- Projected Revenue of PE Therapeutics Market in France
- Projected Revenue of PE Therapeutics Market in Italy
- Projected Revenue of PE Therapeutics Market in Spain
- APAC: Projected Revenue of PE Therapeutics Market (2023-2029; $Millions)
- Projected Revenue of PE Therapeutics Market in Japan
- Projected Revenue of PE Therapeutics Market in India
- Projected Revenue of PE Therapeutics Market in China
- Latin America: Projected Revenue of PE Therapeutics Market (2023-2029; $Millions)
- Projected Revenue of PE Therapeutics Market in Brazil
- Projected Revenue of PE Therapeutics Market in Mexico
- Projected Revenue of PE Therapeutics Market in Argentina
- Middle East & Africa: Projected Revenue of PE Therapeutics Market (2023-2029; $Millions)
- Projected Revenue of PE Therapeutics Market in Turkey
- Projected Revenue of PE Therapeutics Market in Saudi Arabia
- Projected Revenue of PE Therapeutics Market in South Africa
- PE Therapeutics Market Opportunities & Trends
- PE Therapeutics Market Drivers
- PE Therapeutics Market Constraints
- PE Therapeutics Market - Competitive Landscape
- PE Therapeutics Market – Key Vendor Profiles
- PE Therapeutics Market – Other Prominent Vendors
- PE Therapeutics Market - Key Strategic Recommendations
- Research Methodology
- Abbreviations
- About Arizton
Exhibit 1: Projected Revenues of PE Therapeutics in Global (2023-2029; $ Mn)
Exhibit 2: Projected Revenue of PE Therapeutics by SSRIs (2023-2029; $ Mn)
Exhibit 3: Projected Revenue of PE Therapeutics by PDE-5 Inhibitors ($ Mn)
Exhibit 4: Projected Revenues of PE Therapeutics by Anesthetic Agents (2023-2029; $ Mn)
Exhibit 5: Projected Revenues of PE Therapeutics by Others (2023-2029; $ Mn)
Exhibit 6: Projected Revenues of PE Therapeutics by Oral (2023-2029; $ Mn)
Exhibit 7: Projected Revenues of PE Therapeutics by Topical (2023-2029; $ Mn)
Exhibit 8: Projected Revenues of PE Therapeutics by Below 45 years (2023-2029; $ Mn)
Exhibit 9: Projected Revenues of PE Therapeutics by Above 45 years (2023-2029; $ Mn)
Exhibit 10: Projected Revenues of PE Therapeutics in North America (2023-2029; $ Mn)
Exhibit 11: Projected Revenues of PE Therapeutics in US (2023-2029; $ Mn)
Exhibit 12: Projected Revenues of PE Therapeutics in Canada (2023-2029; $ Mn)
Exhibit 13: Projected Revenues of PE Therapeutics in Europe (2023-2029; $ Mn)
Exhibit 14: Projected Revenues of PE Therapeutics in Germany (2023-2029; $ Mn)
Exhibit 15: Projected Revenues of PE Therapeutics in France (2023-2029; $ Mn)
Exhibit 16: Projected Revenues of PE Therapeutics in UK (2023-2029; $ Mn)
Exhibit 17: Projected Revenues of PE Therapeutics in Italy (2023-2029; $ Mn)
Exhibit 18: Projected Revenues of PE Therapeutics in Spain (2023-2029; $ Mn)
Exhibit 19: Projected Revenues of PE Therapeutics in APAC (2023-2029; $ Mn)
Exhibit 20: Projected Revenues of PE Therapeutics in Japan (2023-2029; $ Mn)
Exhibit 21: Projected Revenues of PE Therapeutics in China (2023-2029; $ Mn)
Exhibit 22: Projected Revenues of PE Therapeutics in India (2023-2029; $ Mn)
Exhibit 23: Projected Revenues of PE Therapeutics in Latin America (2023-2029; $ Mn)
Exhibit 24: Projected Revenues of PE Therapeutics in Brazil (2023-2029; $ Mn)
Exhibit 25: Projected Revenues of PE Therapeutics in Mexico (2023-2029; $ Mn)
Exhibit 26: Projected Revenues of PE Therapeutics in Argentina (2023-2029; $ Mn)
Exhibit 27: Projected Revenues of PE Therapeutics in MEA (2023-2029; $ Mn)
Exhibit 28: Projected Revenues of PE Therapeutics in Turkey (2023-2029; $ Mn)
Exhibit 29: Projected Revenues of PE Therapeutics in Saudi Arabia (2023-2029; $ Mn)
Exhibit 30: Projected Revenues of PE Therapeutics in South Africa (2023-2029; $ Mn)
Table 1: Key Market Trends in PE Therapeutics Market
Table 2: Key Market Enablers in PE Therapeutics Market
Table 3: Key Market Constraints in PE Therapeutics Market
Table 4: Strategic Recommendations in PE Therapeutics Market
Interested in this report?
Other Related Reports
Frequently Asked Questions
Download Free Sample
Download free market research reports by Focus Reports covering, industry overview, market size, market share.
Speak with our analyst
Download free market research reports by Arizton covering, industry overview, market size, market share, markets trends.
Our Clients
